South Korea increased 1.7points of Breast Cancer Screening (Survey) in 2019, compared to a year earlier.

Breast Cancer Screening Market is projected to reach USD 16,340.5 million by 2031, at a CAGR of 9.1% from 2023-2031.

The report covers North America Breast Cancer Diagnosis Test and the market is Segmented by Test (Genomic Tests and Imaging Tests) and Geography (United States, Canada, and Mexico). The market provides the value (in USD million) for the above-mentioned segments.

Curated Breast Imaging Subset DDSM Dataset (Mammography)

According to the data, the COVID-19 pandemic strongly affected the number of screenings for breast cancer in Italy. Indeed, screenings decreased 37.6 percent in 2020 in respect to the previous year. This decrease was the greatest in the months from January to May, with an almost 54 percent decrease. This figure shows the percentage change in breast cancer screenings before and during the COVID-19 pandemic in Italy in 2019 and 2020, by time period.

Between 2021 and 2022, about 70.4 percent of women aged 50 to 69 years in Italy had a mammogram. Preventive breast cancer screening through a mammogram every two years is most recommended for those aged 50 to 69 years. Between 2021 and 2022, breast cancer screening was much more common in the Northern Italian regions, with rates often above 80 percent.

Breast cancer screening over time Before 2020, when COVID-19 hit Italy, the share of women between 50 and 69 years undergoing breast cancer screening at least once in the previous two years, had an increasing trend overall. However, the share of women who underwent preventive examinations for breast cancer after 2019 had a considerable decrease compared to the previous years. As a matter of fact, in 2019 the share of women with breast cancer screening amounted to 75.1 percent, while in 2020 it was 72.5 and in 2021 dropped to 68.8 percent.

Cervical cancer screening In Italy, women between the ages of 25 and 64 years are recommended to do a cervical cancer screening every three years. Since 2008, the percentage of women aged 25 to 65 who underwent cervical cancer screening in the previous three years, fluctuated yearly from 75.2 to 81 percent. This peak was reached in 2019 and was followed by a steep decrease in 2020, in correspondence with the spread of COVID-19. Between 2021 and 2022, when the share of women with cervical cancer screening amounted to 77.8 percent in Italy, geographical differences could be observed across the country: among Northern regions, with 84.1 percent of women underwent this screening, while in Southern regions this share amounted to only 69.2 percent.

NHS Breast Screening Programme, England 2020-21

PurposeTo evaluate mammography uptake and subsequent breast cancer diagnoses, as well as the prospect of additive cancer detection via a liquid biopsy multi-cancer early detection (MCED) screening test during a routine preventive care exam (PCE).MethodsPatients with incident breast cancer were identified from five years of longitudinal Blue Health Intelligence® (BHI®) claims data (2014-19) and their screening mammogram and PCE utilization were characterized. Ordinal logistic regression analyses were performed to identify the association of a biennial screening mammogram with stage at diagnosis. Additional screening opportunities for breast cancer during a PCE within two years before diagnosis were identified, and the method extrapolated to all cancers, including those without recommended screening modalities.ResultsClaims for biennial screening mammograms and the time from screening to diagnosis were found to be predictors of breast cancer stage at diagnosis. When compared to women who received a screening mammogram proximal to their breast cancer diagnosis (0-4 months), women who were adherent to guidelines but had a longer time window from their screening mammogram to diagnosis (4-24 months) had a 87% increased odds of a later-stage (stages III or IV) breast cancer diagnosis (p-value

Breast cancer is one of the most prevalent types of cancer and the leading type of cancer death. Mammography is the recommended imaging modality for periodic breast cancer screening. A few datasets have been published to develop computer-aided tools for mammography analysis. However, these datasets either have a limited sample size or consist of screen-film mammography (SFM), which have been replaced by full-field digital mammography (FFDM) in clinical practices. This project introduces a large-scale full-field digital mammography dataset of 5,000 four-view exams, which are double read by experienced mammographers to provide cancer assessment and breast density following the Breast Imaging Report and Data System (BI-RADS). Breast abnormalities that require further examination are also marked by bounding rectangles.

Breast cancer is the second leading cause of cancer death for women in the United States. However, breast cancer burden is not evenly distributed in the population. An estimated 6-15% of women are at high (≥20% lifetime risk) risk for breast cancer based on personal health factors, family breast cancer history, or pathogenic genetic mutations (e.g., BRCA1/2). Compared to the general population, these women are nearly twice as likely to develop breast cancer.

For high risk women, breast cancer screening guidelines include annual mammography and supplemental breast magnetic resonance imaging (MRI). However, only 1-7% of high risk women receive screening breast MRI. Thus, there is an urgent need to examine and address barriers to screening breast MRI among women with high breast cancer risk.

The aims of this study are twofold: (1) assess factors influencing screening breast MRI utilization in a community-based sample of women at high risk for breast cancer (N=200); and (2) confirm, refine, or expand our conceptual model of screening breast MRI utilization through in-depth semi-structured qualitative interviews with a subset of Aim 1 patients (N=30).

The global breast cancer screening tests market was valued at US$ 1.9 Billion in 2022 and is expected to reach US$ 4.4 Billion by 2033. The imaging tests segment with around 54.3% value share, has topped the global market within the product category in 2022 and is expected to grow at a CAGR of close to 7.8% over the forecast period (2023 to 2033).

Data Points	Market Insights
Market Value 2022	US$ 1.9 Billion
Market Value 2023	US$ 2.1 Billion
Market Value 2033	US$ 4.4 Billion
CAGR 2023 to 2033	7.8%
Market Share of Top 5 Countries	54.5%
Key Market Players	AstraZeneca, Novartis, Sanofi, Pfizer, Bayer AG, GlaxoSmithKline plc, and Siemens Healthineers, Hologic Inc.

Report Scope as Per Breast Cancer Screening Test Industry Analysis

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2017 to 2022
Market Analysis	US$ Million for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, UK, Spain, BENELUX, Russia, China, Japan, South Korea, India, Indonesia, Thailand, Philippines, Malaysia, Australia, New Zealand, GCC countries, Türkiye, Northern Africa and South Africa.
Key Market Segments Covered	Diagnostic Test Type, End User, and Region
Key Companies Profiled	AstraZeneca Novartis Sanofi Pfizer Bayer AG GlaxoSmithKline plc Siemens Healthineers Hologic Inc. General Electric Company Koninklijke Philips NV Fujifilm Holdings A&G Pharmaceutical, Inc. Biocrates Life Sciences AG Metabolomic Technologies, Inc. Myriad Genetics OncoCyte Corporation POC Medical Systems, Inc. Hologic, Inc. Provista Diagnostics, Inc. BioTime, Inc.
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Pricing	Available upon Request

NHS Breast Screening Programme, England 2021-22

Cancer screening coverage - breast cancer (% eligible women screened adequately within previous 3 years)

Context

This dataset includes data from a random sample of 20,000 digital and 20,000 film-screen mammograms received by women age 60-89 years within the Breast Cancer Surveillance Consortium (BCSC) between January 2005 and December 2008. Some women contribute multiple examinations to the dataset. Data is useful in teaching about data analysis, epidemiological study designs, or statistical methods for binary outcomes or correlated data.

Content

The data set contains 39998 rows and 13 cols. Attributes are described as follows:

| Field Name | **Type (Format) |Description** | Age_At_The_Time_Of_Mammography| number|Patient's age in years at time of mammogram | --- | --- |--- | Radiologists_Assessment| string |Radiologist's assessment based on the BI-RADS scale | --- | --- |--- |Is_Binary_Indicator_Of_Cancer_Diagnosis | boolean |Binary indicator of cancer diagnosis within one year of screening mammogram (false= No cancer diagnosis, true= Cancer diagnosis) | --- | --- |--- |Comparison_Mammogram_From_Mammography | string |Comparison mammogram from prior mammography examination available | --- | --- |--- | Patients_BI_RADS_Breast_Density | string|Patient's BI-RADS breast density as recorded at time of mammogram | --- | --- |--- | Family_History_Of_Breast_Cancer| string |Family history of breast cancer in a first degree relative | --- | --- |--- | Current_Use_Of_Hormone_Therapy | string |Current use of hormone therapy at time of mammogram | --- | --- |--- | Binary_Indicator | string |Binary indicator of whether the woman had ever received a prior mammogram | --- | --- |--- | History_Of_Breast_Biopsy |string |Prior history of breast biopsy | --- | --- |--- | Is_Film_Or_Digital_Mammogram | boolean |Film or digital mammogram (true=Digital mammogram, false=Film mammogram) | --- | --- |--- |Cancer_Type | string |Type of cancer | --- | --- |---

Acknowledgements

We acknowledge the Breast Cancer Surveillance Consortium (BCSC) for making this data set available for research purposes.

All variables are presented in an excel sheet (xlxs). The objective of this study is to analyze whether women's level of knowledge about the benefits and harms of screening, their time perspective and their concern about breast cancer providing detailed information on the benefits and adverse effects of breast cancer screening affects, directly or indirectly, affects the intention to participate in it. The database includes variables that allow us to construct the outcome of informed choice, a variable that combines knowledge, attitudes and intentions. Other variables that reflect women's perceptions of how their decision to participate, or not, in screening affects them, now or in the future, are also collected: decisional conflict; anxiety about screening participation; concern about breast cancer; anticipated regret; time perspective; perceived importance of the benefits/harms of screening.

Women between the ages of 50 to <71 are invited for regular breast screening (every three years) under a national programme. Screening is intended to reduce mortality by detecting breast cancer at an early stage when there is a better chance of successful treatment. This report presents information about the NHS Breast Screening Programme in England in 2019-20 and includes data on women invited for breast screening, coverage, uptake of invitations, outcomes of screening and cancers detected. The publication also features an online interactive dashboard to complement the existing publication resources.

OBJECTIVE To assess findings of mammography of and interventions resulting from breast cancer screening in women aged 40-49 years with no increased risk (typical risk) of breast cancer. METHODS This cross-sectional study evaluated women aged 40-49 years who underwent mammography screening in a mastology reference center in Recife, PE, Northeastern Brazil, between January 2010 and October 2011. Women with breast-related complaints, positive findings in the physical examination, or high risk of breast cancer were excluded. RESULTS The 1,000 mammograms performed were classified into the following Breast Imaging-Reporting and Data System (BI-RADS) categories BI-RADS 0, 232; BI-RADS 1, 294; BI-RADS 2, 294; BI-RADS 3, 16; BI-RADS 4A, 2; BI-RADS 5, 1. There was one case of grade II invasive ductal carcinoma and various interventions, including 469 ultrasound scans, 53 referrals to mastologists, 11 cytological examinations, and 8 biopsies. CONCLUSIONS Mammography screening in women aged 40-49 years with typical risk of breast cancer led to the performance of other interventions. However, it also resulted in increased costs without demonstrable efficacy in decreasing mortality.

Updated 4 April 2018: A data quality issue has been identified which relates to first invitation uptake data for a subset of Breast Screening Units in 2016-17. Additional footnotes have been added to the Main Report, Data Tables, Appendices document and the Interactive Dashboard. Women between the ages of 50 and 70 are invited for regular breast screening (every three years) under a national programme. Screening is intended to reduce mortality by detecting breast cancer at an early stage when there is a better chance of successful treatment. This report presents information about the NHS Breast Screening Programme in England in 2016-17 and includes data on women invited for breast screening, coverage, uptake of invitations, outcomes of screening and cancers detected. The publication also features an online interactive dashboard to complement the existing publication resources. The dashboard can be accessed by clicking on the icon above or by clicking on the link in the resources section below. This tool is in Microsoft PowerBI which does not fully support all accessibility needs. If you need further assistance, please contact us for help.

This CBIS-DDSM (Curated Breast Imaging Subset of DDSM) is an updated and standardized version of the Digital Database for Screening Mammography (DDSM) . The DDSM is a database of 2,620 scanned film mammography studies. It contains normal, benign, and malignant cases with verified pathology information. The scale of the database along with ground truth validation makes the DDSM a useful tool in the development and testing of decision support systems. The CBIS-DDSM collection includes a subset of the DDSM data selected and curated by a trained mammographer. The images have been decompressed and converted to DICOM format. Updated ROI segmentation and bounding boxes, and pathologic diagnosis for training data are also included. A manuscript describing how to use this dataset in detail is available at https://www.nature.com/articles/sdata2017177.

Published research results from work in developing decision support systems in mammography are difficult to replicate due to the lack of a standard evaluation data set; most computer-aided diagnosis (CADx) and detection (CADe) algorithms for breast cancer in mammography are evaluated on private data sets or on unspecified subsets of public databases. Few well-curated public datasets have been provided for the mammography community. These include the DDSM, the Mammographic Imaging Analysis Society (MIAS) database, and the Image Retrieval in Medical Applications (IRMA) project. Although these public data sets are useful, they are limited in terms of data set size and accessibility.

For example, most researchers using the DDSM do not leverage all its images for a variety of historical reasons. When the database was released in 1997, computational resources to process hundreds or thousands of images were not widely available. Additionally, the DDSM images are saved in non-standard compression files that require the use of decompression code that has not been updated or maintained for modern computers. Finally, the ROI annotations for the abnormalities in the DDSM were provided to indicate a general position of lesions, but not a precise segmentation for them. Therefore, many researchers must implement segmentation algorithms for accurate feature extraction. This causes an inability to directly compare the performance of methods or to replicate prior results. The CBIS-DDSM collection addresses that challenge by publicly releasing an curated and standardized version of the DDSM for evaluation of future CADx and CADe systems (sometimes referred to generally as CAD) research in mammography.

Please note that the image data for this collection is structured such that each participant has multiple patient IDs. For example, participant 00038 has 10 separate patient IDs which provide information about the scans within the IDs (e.g. Calc-Test_P_00038_LEFT_CC, Calc-Test_P_00038_RIGHT_CC_1). This makes it appear as though there are 6,671 patients according to the DICOM metadata, but there are only 1,566 actual participants in the cohort.